SCHEMBL23200355

SCHEMBL23200355

Cc1ccc(NC(=O)c2ccccc2NS(=O)(=O)c2cccc(C(F)(F)F)c2)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.67
KMT2A Q03164 4/20 0.67
GAA P10253 1/20 0.67
SLC20A2 Q08357 1/20 0.63
SLC20A1 Q8WUM9 1/20 0.63
SLC10A2 Q12908 1/20 0.61
SLC10A1 Q14973 1/20 0.61
SLC10A6 Q3KNW5 1/20 0.61
RXFP1 Q9HBX9 8/20 0.61
POLB P06746 2/20 0.60
RECQL P46063 2/20 0.60
LMNA P02545 4/20 0.58
HTT P42858 3/20 0.58
TP53 P04637 1/20 0.58
MAPT P10636 1/20 0.58
XBP1 P17861 1/20 0.58
ALOX12 P18054 1/20 0.58
NPSR1 Q6W5P4 1/20 0.58
KDM4E B2RXH2 2/20 0.55
HPGD P15428 2/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30926890 1.00 MEN1 (0.67) MEN1KMT2AGAASLC20A2SLC20A1
SCHEMBL7128448 0.91 MEN1 (0.76) MEN1KMT2AGAASLC20A2SLC20A1
SCHEMBL30926577 0.91 MEN1 (0.76) MEN1KMT2AGAASLC20A2SLC20A1
SCHEMBL27181165 0.90 MEN1 (0.68) MEN1KMT2AGAASLC20A2SLC20A1
SCHEMBL30926819 0.90 MEN1 (0.68) MEN1KMT2AGAASLC20A2SLC20A1
SCHEMBL7120286 0.89 SLC20A2 (0.74) MEN1KMT2AGAASLC20A2SLC20A1
SCHEMBL23200349 0.88 KDM4E (0.63) MEN1KMT2ASLC10A2SLC10A1SLC10A6
SCHEMBL28454669 0.85 MEN1 (0.64) MEN1KMT2AGAASLC20A2SLC20A1
SCHEMBL30927042 0.85 MEN1 (0.64) MEN1KMT2AGAASLC20A2SLC20A1
SCHEMBL27179805 0.85 MEN1 (0.64) MEN1KMT2AGAASLC20A2SLC20A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4580404-A2 SULFONAMIDE APYRASE INHIBITORS Texas Crop Science, Inc. (US) 2025-07-09 EP claimed
US-12065421-B2 Inhibitors of oplophorus luciferase-derived bioluminescent complexes PROMEGA CORPORATION (US) 2024-08-20 US claimed
EP-4140991-B1 INHIBITORS OF OPLOPHORUS LUCIFERASE-DERIVED BIOLUMINESCENT COMPLEXES PROMEGA CORP (US) 2024-05-15 EP claimed
US-20240099300-A1 SULFONAMIDE APYRASE INHIBITORS TEXAS CROP SCIENCE, INC. 2024-03-28 US claimed
WO-2024050041-A2 SULFONAMIDE APYRASE INHIBITORS TEXAS CROP SCIENCE (US) 2024-03-07 WO claimed
EP-4140991-A1 INHIBITORS OF OPLOPHORUS LUCIFERASE-DERIVED BIOLUMINESCENT COMPLEXES Promega Corporation (US) 2023-03-01 EP claimed
US-20220365086-A1 INHIBITORS OF OPLOPHORUS LUCIFERASE-DERIVED BIOLUMINESCENT COMPLEXES PROMEGA CORPORATION 2022-11-17 US claimed
US-12065421-B2 Inhibitors of oplophorus luciferase-derived bioluminescent complexes PROMEGA CORPORATION (US) 2024-08-20 US disclosed
EP-4140991-B1 INHIBITORS OF OPLOPHORUS LUCIFERASE-DERIVED BIOLUMINESCENT COMPLEXES PROMEGA CORP (US) 2024-05-15 EP disclosed
US-20240099300-A1 SULFONAMIDE APYRASE INHIBITORS TEXAS CROP SCIENCE, INC. 2024-03-28 US disclosed
WO-2024050041-A2 SULFONAMIDE APYRASE INHIBITORS TEXAS CROP SCIENCE (US) 2024-03-07 WO disclosed
EP-4140991-A1 INHIBITORS OF OPLOPHORUS LUCIFERASE-DERIVED BIOLUMINESCENT COMPLEXES Promega Corporation (US) 2023-03-01 EP disclosed
US-20220365086-A1 INHIBITORS OF OPLOPHORUS LUCIFERASE-DERIVED BIOLUMINESCENT COMPLEXES PROMEGA CORPORATION 2022-11-17 US disclosed
EP-3802514-B1 INHIBITORS OF OPLOPHORUS LUCIFERASE-DERIVED BIOLUMINESCENT COMPLEXES PROMEGA CORP (US) 2022-08-03 EP disclosed
US-11390599-B2 Inhibitors of oplophorus luciferase-derived bioluminescent complexes PROMEGA CORPORATION (US) 2022-07-19 US disclosed
EP-3802514-A1 INHIBITORS OF OPLOPHORUS LUCIFERASE-DERIVED BIOLUMINESCENT COMPLEXES Promega Corporation (US) 2021-04-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220365086-A1 INHIBITORS OF OPLOPHORUS LUCIFERASE-DERIVED BIOLUMINESCENT COMPLEXES LUC7L2, LYPLAL1, GUSB MEN1 2157/4885KMT2A 2984/4885GAA 937/4885
US-12065421-B2 Inhibitors of oplophorus luciferase-derived bioluminescent complexes LUC7L2, LYPLAL1, GUSB MEN1 2157/4885KMT2A 2984/4885GAA 937/4885
US-20240099300-A1 SULFONAMIDE APYRASE INHIBITORS APEH, ARSA, DNPEP MEN1 4795/4885KMT2A 2544/4885GAA 159/4885
US-11390599-B2 Inhibitors of oplophorus luciferase-derived bioluminescent complexes LUC7L2, LYPLAL1, GUSB MEN1 2157/4885KMT2A 2984/4885GAA 937/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.